CoChat
Sign Up
Cited by 63Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychological Treatments and Disorders

The DOI matches its Crossref record, with a small difference in title or year; 85 of the 85 references it cites were found in a registry or an index.

Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?

Olver, James S., Burrows, Graham D., Norman, Trevor R.·2001·CNS Drugs
DOI 10.2165/00023210-200115120-00004
Open this paper in CoChat — free account

Abstract

Third-generation antidepressants are a group of antidepressant agents of variable action, not confined to serotonin reuptake inhibition. These agents include venlafaxine, reboxetine, nefazodone and mirtazapine. Claims have been made for these agents in terms of improved efficacy, faster speed of onset of effect and greater safety in the treatment of depression compared with previous medications, such as the selective serotonin reuptake inhibitors (SSRIs). This article reviews the evidence for these improvements. Thirty active comparator studies were reviewed involving the third-generation antidepressant agents. While there were isolated reports of improvements over comparator agents for venlafaxine, reboxetine and mirtazepine, there were no convincing differences between third-generation agents and comparators in terms of overall efficacy, relapse prevention and speed of onset. The third-generation antidepressants were, however, of equivalent safety to SSRIs and maintained improvements in safety over first-generation agents.

Overview

Integrity signals

Registry

Crossref · 10.2165/00023210-200115120-00004

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 85 references

Research works printed but not linked: 16

  1. Riva, 1989, J Drug Develop, 1, 243
  2. Davis, 1996, Drugs, 5, 389
  3. Dierick, 1996, Prog Neuropsychopharmacol Biol Psychiatry, 20, 7
  4. Feighner, 1989, Psychopharmacol Bull, 25, 219
  5. Fontaine, 1994, J Clin Psychiatry, 55, 234
  6. Smith, 1990, Psychopharmacol Bull, 26, 192
  7. Bremner, 1995, J Clin Psychiatry, 56, 519
  8. Entsuah, 1996, Int Clin Psychopharmacol, 11, 137
  9. Anton, 1994, Psychopharmacol Bull, 30, 165
  10. Derivan, 1995, Psychopharmacol Bull, 31, 23
  11. Prien, 1985, Hosp Community Psychiatry, 36, 513
  12. Feighner, 1995, J Clin Psychiatry, 56, 574
  13. Baldwin, 2000, Rev Contemp Pharmacother, 11, 321
  14. Jannuzzo, 1995, Eur Neuropsychopharmacol, 5, 300
  15. Hoes, 1996, Int Clin Psychopharmacol, 11, 147
  16. Stormer, 2000, Drug Metab Dispos, 28, 1168

Cited by

Sorted by citations

See all 63

Related

See all

Metadata

Authors
Olver, J. S., Burrows, G. D., & Norman, T. R.
Affiliations
The University of Melbourne (AU)
Corresponding author
Norman, Trevor R.
ORCID
Norman, Trevor R.
Venue
CNS Drugs
Publisher
Springer Science and Business Media LLC
Published
2001
Volume
15
Issue
12
Pages
941-954
ISSN
1172-7047 (ISSN-L)
DOI
10.2165/00023210-200115120-00004
OpenAlex
W2087328751
Cited by
63
References
85
Citations by year
2025: 2 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2018: 3 · 2016: 2 · 2015: 2 · 2014: 4 · 2013: 3 · 2012: 3
FWCI
0.56
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
venlafaxine, reboxetine, nefazodone, mirtazapine, depression, selective serotonin reuptake inhibitors, antidepressant efficacy, relapse prevention, onset of action, drug safety
MeSH terms
Antidepressive Agents, Clinical Trials as Topic, Depressive Disorder, Humans, Selective Serotonin Reuptake Inhibitors, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review